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Despite the declaration of tuberculosis (TB) as a global emergency by the world health organization 
(WHO) about 20 years ago, the worldwide problem of this disease has worsened due to increased drug 
resistance of tuberculosis bacilli and acquired immune deficiency syndrome (AIDS) pandemic. 
Consequently, fight against multidrug and extensively drug-resistant TB is a high priority for public 
health and research. The present work describes the isolation of a Bacillus pumilus strain secreting a 
metabolite of protein nature capable of inhibiting mycobacterial growth (Mycobacterium smegmatis, 
Mycobacterium aurum and Mycobacterium bovis BCG). This metabolite is not toxic, accumulates within 
the macrophage and inactivates the bacilli with a comparable efficiency to that of the pure commercial 
antimycobacterial substance Amikacin. 
 





At the beginning of the twenty first century, tuberculosis 
remains a disease of the present. It is the primary cause 
of infectious mortality in the world (Billy and Perronne, 
2004). In 2007, the number of new tuberculosis cases 
was estimated at about 9.7 million and the number of 
deaths at 1.8 million (WHO, 2009). Although the disease 
is ubiquitous, 80% of the worlds’ tuberculosis cases have 
been registered in Asia (55%) and Africa (31%) (WHO, 
2009). The causes of the failure to control tuberculosis 
are multi-factorial and principally due to the advent of 
AIDS (acquired ammuno deficiency syndrome), the 
relative efficiency of the bacillus calmette-guerin (BCG) 
vaccine (Billy and Lévy-Bruhl, 2007) as well as the 
expansion of Mycobacterium tuberculosis multi and 
extensive drug resistant strains (Danilchanka et al., 2008; 
Gruber et al., 2008). Acquired drug resistance has been 




*Corresponding author. E-mail: mhiraqui@yahoo.fr. 
inappropriate use of antibiotics. Mono-resistance to 
antituberculosis drugs is not particularly a threat whereas 
multidrug resistance to drugs used in standard 
management schemes is of major concern (Migliori et al., 
2002). 
Consequently, along with synthetic drugs, the search 
for natural antibiotics from novel sources, such as micro-
organisms from extreme biological niches, is primordial in 
the fight against this dreadful disease (Dharmarajan et 
al., 2006). 
The antibiotics used today are derived principally from 
a restricted group of microorganisms of the genera 
Penicillium, Streptomyces, Cephalosporium, 
Micromonospora and Bacillus. In the pharmaceutical 
industry, several highly important antimicrobial peptides, 
such as Polymyxin, Gramicidin, Tyrocidine, Subtilin, 
Bacilysin etc., are produced by species from the genus 
Bacillus (Katz and Demain, 1977; Mendo et al., 2004). 
The majority of these antibiotics are peptides of low 
molecular weight, produced via a nonribosomal 
biosynthetic pathway that depends  on  specific  enzymes  
  




called peptide synthetases. These peptides possess a 
large range of biological activity (Nicolas and Mor, 1995). 
They are mainly active against Gram positive bacteria; 
nevertheless, compounds such as Polymixin, Colistin and 
Circulin inhibit Gram negative organisms, while 
bacillomycin, mycobacillin, and fungistatin are active 
against yeasts and fungi (Katz and Demain, 1977). 
The present investigation describes the isolation of a 
strain of Bacillus pumilus that secretes a metabolite of 
protein nature showing antimycobacterial activity. This 
noncytotoxic metabolite is also capable of accumulating 
inside macrophages, resisting the hostile conditions 
within the phagocytes and specifically inactivating the 
bacilli with efficiency comparable to that of Amikacin. 
 
 
MATERIALS AND METHODS 
 
Bacteria and culture conditions 
 
The mycobacteria used include: 
 
1. Mycobacterium aurum A+: A nonpathogenic mycobacteria with a 
generation time of approximately 6 h. M. aurum is considered a 
surrogate model that can be used to evaluate the effect of 
substances the on growth of M. tuberculosis (Chung et al., 1995); 
2. Mycobacterium smegmatis MC2 155: Atypical nonpathogenic 
mycobacteria with a generation time of approximately 3 h; 
3. Mycobacterium bovis BCG IPP: The vaccine strain; 
4. Escherichia coli DH5α. 
 
The mycobacteria were grown on Löwenstein Jensen (LJ) and 
Sauton media, at 37°C (Allen, 1998; Papa et al., 1987). 
The E. coli strain was cultivated on Luria Bertani (LB) medium 
(peptone (Biokarps diagnostics, Beauvais, France), 10 g/l; yeast 
extract (Biokarps diagnostics, Beauvais, France), 5 g/l; Sodium 
Chloride (Riedel- de Haën, Seelze, Germany), 10 g/l). 
 
 
Screening for bacterial strains with antimycobacterial activity 
 
Soil samples were collected from selected Moroccan biotopes. The 
samples were collected, after the removal of the first centimeters of 
soil, to a depth of 5 to 10 cm. These were placed, with the aid of a 
sterile spatula, over a sterile aluminum sheet for removal of gross 
debris (stones etc.) after which they were poured into a sterile vial 
for transport to the laboratory where they were treated 
independently for bacterial isolation as follows: Four grams of soil 
were mixed into 36 ml of sterile saline (NaCl 9 g/l) and vortexed for 
2 h. A series of decimal dilutions of this suspension (from 10-1 to 10-
7) were prepared in LB broth. An aliquot of 100 µL of each dilution 
was spread over LB-agar previously inoculated with M. aurum A+ or 
M. smegmatis cultures of approximately 106 CFU/ml. After incubi-
tion at 37°C for 48 h, bacterial clones surrounded by an inhibition 
zone were subcultured. One of the isolated clones having shown 
important activity was selected for the following study. 
 
 
Identification of the antimycobacterial producing strain  
 
The identification of the isolate showing antimycobacterial activity 
was carried out using polymerase chain reaction (PCR) 
amplification and sequencing of the 16S rRNA gene. For this, 





1961). Universal primers were used to amplify the 16S rDNA, fD1 
(5’ AGAGTTTGATCCTGGCTCAG 3’) and rP2 
(5’TACGGCTACCTTGTTACGACTT 3’) (Weisberg et al., 1991). 
These primers can be used to amplify the eubacterial 16S rRNA 
gene (Weisberg et al., 1991), including from the genus Bacillus 
(Weisberg et al., 1991; Drancourt et al., 2000). For PCR 
amplification the following program was used as follows : 94°C for 5 
min, 35 cycles of (94°C for 30 s, 55°C for 45 s, 72°C for 1min 30 s), 
72°C for 10 min. The PCR products were then sequenced using the 
ABI PRISM sequencer (ABI Prism 310 genetic analyser, applied 
biosyste). The 16S rRNA sequences obtained were compared to 
those in the Gen Bank, EMBL, DDJB and PDB databases using the 
BLAST N 2.2.11 program of the national center for biotechnology 
information (NCBI) website.  
 
 
Extraction of the antimycobacterial substances by organic 
solvents 
 
In order to show that the antimycobacterial effect of the bacterial 
isolate was due to secreted substances, an extraction procedure 
using two organic solvents (Ethyl Acetate and Ether) was used 
according to the following protocol: 
The isolate was cultured under agitation in 100 ml of LB broth for 
24 h at 37°C. After centrifugation at 6000 rpm for 10 min, the 
supernatant was recovered then filtered using a filter of 0.22 µm of 
porosity. The filtrate was added to an equal volume of organic 
solvent and kept under agitation at ambient temperature for 1 h. 
The extract obtained was evaporated under vacuum at 37°C using 
a rotary evaporator. The dried residue was dissolved in 1 ml of 
sterile distilled water, filtered and used to measure the 
antimycobacterial activity using the “well method” as follows. 
Aliquots of 100 µl from mycobacterial cultures (M. aurum A+, M. 
smegmatis), containing approximately 106 CFU/ml, were spread on 
LB-agar where wells, 6 mm in diameter, had previously been cut. 
100 µl of the prepared organic extract was deposited in the wells. 
The plates were incubated at 37°C. The diameters of the inhibition 
zones were measured after 48 h of incubation at 37°C. The test 
was repeated three times. 
Experimental controls included LB-agar plates inoculated with the 
same mycobacterial strains but when the wells were filled with 100 
µl of an E. coli culture extract prepared in an identical manner as 
described for the bioactive isolate. 
 
 
Characterisation of the protein nature of the antimycobacterial 
metabolite 
 
Purification of the antimycobacterial metabolite was carried out 
according to the method described by Wu et al. (2005). The isolate 
was cultured under agitation in 100 ml of LB broth for 24 h at 37°C. 
After centrifugation of the culture at 6000 rpm for 10 min, the 
supernatant was recovered and filtered. Precipitation using a 
saturated solution of Ammonium Sulfate (80% ammonium sulfate) 
was carried out overnight under agitation at 4°C. After 
centrifugation at 10000 rpm for 30 min, the pellet was suspended in 
2 ml of Potassium Phosphate buffer (pH 6; 50 mM) and dialysed 
against the same buffer at 4°C for 24 h. The buffer was substituted 
several times to improve dialysis efficiency. The antimycobacterial 
activity of the dialysate was tested against M. aurum A+ using the 
diffusion method.  
The precipitated metabolite was tested regarding its sensitivity to 
degradation by proteinase K at a final concentration of 1 mg/ml (Wu 
et al., 2005). After addition of proteinase K, the sample was 
incubated at 37ºC for 3 h. Experimental controls included: samples 
prepared under the same conditions except for using 100 ml of LB 






without enzyme treatment and the enzymatic solution alone. The 
antimycobacterial effect of the different preparations was examined 
using the well method against M. aurum A+. The tests were 
repeated three times. 
 
 
Study of the inhibitory activity of the antimycobacterial 
metabolite against M. smegmatis hosted by macrophages 
 
Murin peritoneal macrophages isolation 
 
Murin peritoneal macrophages were isolated according to the 
protocol described by Sosunov et al. (2007). After the anesthesia of 
the mouse, 20 ml of cold Hanks balanced salt solution was injected 
into abdomen. After 15 min, a short abdominal incision was 
performed and the cellular suspension recovered by aspiration 
using a syringe. After a washing step using the Hanks' balanced 
salt solution, the cells were suspended in RPMI-1640 medium 
supplemented with 2% fetal calf serum. The cellular suspension at 
a density of 5.105 cells per well was added to 96-well microtitration 
plates and incubated for 2 h at 37°C in 5% CO2 atmosphere for 
cellular adhesion. Macrophage viability, determined using the 
trypan bleu exclusion method, was 92%. 
 
 
Cytotoxicity assay  
 
Cytotoxicity of the antimycobacterial metabolite was evaluated by 
neutral red uptake by the murine peritoneal macrophages (Repetto 
et al., 2008). Only live cells are able to fix neutral red. The 
macrophages were seeded into 96-well culture plates containing 
RPMI-1640 medium at a density of 5.105 cells per well in the 
presence of the antimycobacterial metabolite (crude protein extract 
obtained by Ammonium Sulfate precipitation), 0.25% sodium 
dodecyl sulphate (SDS) (used as a cytotoxic control) or the protein 
extract from the LB broth without inoculums. After 72 h incubation, 
the wells were washed with Hanks balanced salt solution, and then 
filled with a 0.075% neutral red solution in RPMI-1640 medium. 
After 2 h of incubation, the wells were again washed until the all 
traces of the dye were eliminated and the absorbance at 540 nm of 
each well was read on a plate reader. 
 
 
Infection of macrophages by M. smegmatis  
 
Adherent macrophages in the wells of the 96-well microtitration 
plates were infected by 7.105 bacilli/well. M. smegmatis 
phagocytosis was favored by incubation of the macrophages for 4 h 
at 37°C in 5% CO2 atmosphere (Rastogi et al., 1987). After 
phagocytosis, the culture medium was removed from the wells, and 
the cells were treated with 10 µg/ml amikacin for 1 h. This treatment 
was followed by several washings, with Hanks balanced salt 
solution, to eliminate extracellular bacilli (Sharbati-Tehrani et al., 
2005; Rastogi et al., 1991; 1987). 
 
 
Protein extracts activity against M. smegmatis hosted by 
macrophages  
 
Crude protein extract, obtained by ammonium sulfate precipitation, 
in solution in RPMI-1640 medium was added to the wells containing 
the M. smegmatis infected macrophages. Intercellular persistence 
was determined by counting mycobacterial colony forming units 
(CFU) at 4, 12, 24, 48, 72 and 96 h after the adding of the 
antimycobacterial metabolite. For this, intracellular mycobacteria 
were recovered after lysis of the macrophages using 0.25% SDS 
solution. After centrifugation, the SDS was eliminated and the bacilli  




suspension plated on LB-agar. CFU counts initiated after 72 h of 
incubation at 37°C. As described by Rastogi et al. (1987), and 
confirmed by our work, the SDS did not show any effect on 
mycobacterial viability. Results were expressed as the proportion of 
bacilli surviving treatment by the bioactive metabolite. These results 
were compared to those obtained using untreated macrophages or 
macrophages treated with amikacin at 200 ug/mL (Sharbati-Tehrani 
et al., 2005). 
 
 
RESULTS AND DISCUSSION 
 
Isolation of a bacterial strain secreting a metabolite 
with antimycobacterial effect 
 
The bacterial isolate produced an inhibition zone in 
cultures of M. aurum A+ and M. smegmatis on LB agar. 
The filtrate, from a subculture of this clone, confirmed this 
result showing that the isolate secrets an active 
substance capable of inhibiting mycobacterial growth 
(Table 1). Results in Table 1, also show that the organic 
solvents used (Ethyl Acetate and Ether) were able to 
extract and concentrate the active substance from the 




Identification of the isolate 
 
The identification of the isolate, showing the observed 
activity, was carried out by 16S rDNA sequencing. This 
molecular approach is the most currently used in 
bacterial phylogeny (Woo et al., 2008; Mignard and 
Flandrois, 2006; Woese et al., 1990). It has led to the 
creation of large databases (Van de Peer et al., 1999; 
Maidack et al., 1996) and its application has been used in 
the identification of environmental bacteria as well as 
“virtual” bacteria impossible to grow in culture (Tortoli, 
2003; Relman et al., 1992; Strous et al., 1999). This 
identification assigned the isolate to the genus Bacillus 
showing 100% similarity with B. pumilus (Accession 
number: HQ625388). 
Bacillus is highly ubiquitous in soil, and is comprised of 
several species synthesizing a considerable number of 
antibiotics with different chemical structures (Wu et al., 
2005). Amongst these species, we mention Bacillus 
subtilis (more than 66 different peptides used for their 
antibacterial activity), Bacillus brevis (approximately 23 
molecules), Bacillus licheniformis, Bacillus polymyxa, B. 
pumilus, and Bacillus circulans (Katz and Demain, 1977). 
 
 
Characterization of the protein nature of the active 
substance from the B. pumilus isolate 
 
The antimycobacterial metabolite, purified by ammonium 
sulfate precipitation, was capable of inhibiting M. aurum 
A+ growth (Table 2). This activity is lost  in  the  presence  
  




Table 1. Antimycobacterial activity of the bacterial isolate (measured in mm). 
 
Microorganism Filtrate Ethyl acetate extract Ether extract 
M. smegmatis 9 ± 0 28 ± 0.5 22 ± 1 
M. aurum A+ 10.5 ± 0.7 29.5 ± 0.7 25 ± 0 
 




Table 2. Characterization of the protein nature of the antimycobacterial metabolite. 
 
Variables 
Inhibition diameters against  M. aurum A+  (mm) 
Without  treatment with 
proteinase K 
After treatment with 
proteinase K 
Controls 
T1 T2 T3 
ASP 31 ± 1.4 0 0 0 0 
EAE 29.5 ± 0.7 0 0 0 0 
EE 25 ± 0.0 0 0 0 0 
 
ASP: Ammonium sulfate precipitate; EAE: Ethyl Acetate extract; EE: Ether extract; T1:  Ammonim sulphate precipitate of sterile LB medium; T2: 





of proteinase K. These results were also obtained with 
the Ethyl Acetate and Ether extracts (Table 2), showing 
that the active substance, responsible for the observed 
activity, is of protein nature. This is in agreement with 
bibliographical data showing that Bacillus produces 
antimicrobial substances of protein nature (Wu et al., 
2005). These molecules are essentially active against 
Gram-positive bacteria, nevertheless compounds such as 
polymixin and colistin inhibit Gram-negative forms 
(Bottone and Peluso, 2003), whereas Bacillomycin, 
Mycobacillin, and Fungistatin are active against yeasts 
and fungi (Katz and Demain, 1977). Bottone and Peluso 
(2003) have reported the inhibition of species from the 
genera Mucoraceae and Aspergillus by an antifungal 
compound produced by B. pumilus. This species also 
showed antibacterial effects inhibiting Staphylococcus 
aureus and d’Enterococcus faecalis resistant strains 
through a Bacteriocin Pumilicin 4 (Aunpad and Na-
Bangchang, 2007). This species is also known for the 
elaboration of other antimicrobial peptides such as 
Micrococcin P, Pumilin and Tetain (Katz and Demain, 
1977). Our work described for the first time was the 
antimycobacterial activity of a strain of B. pumilus 
isolated from Moroccan soil. The activity was shown to be 
due to a metabolite of protein nature for which the 





Amongst the hundreds of natural antibiotics, only few are 
sufficiently nontoxic for clinical use. For this reason, the 
cytotoxicity of the antimycobacterial agent was evaluated 
as well as its effect on mycobacteria within macrophages. 
As shown in Figure 1, peritoneal macrophages treated 
with the antimycobacterial substance or the protein 
extract from LB medium (crude protein extract obtained 
by ammonium sulfate precipitation) fixed neutral red in 
the same manner as untreated macrophages. However, 
macrophages treated with SDS were almost all lysed and 
did not fix neutral red. These results (Figure 1) indicate 
that the active substance of the isolated strain did not 




Study of the activity of the antimycobacterial 
metabolite against M. smegmatis hosted by 
macrophages 
 
Figure 2 shows results of the effect of the metabolite 
against M. smegmatis infecting macrophages. In the 
absence of this metabolite, the elimination of intracellular 
bacilli requires more than 4 days. In the presence of 
amikacin or of the active substance produced by the B. 
pumilus strain, the elimination of M. smegmatis is much 
more rapid. Indeed, the majority of the bacilli are 
inactivated within 24 h in the presence of the metabolite. 
These results (Figures 1 and 2; Tables 1 and 2) show 
that the active substance is effective not only in vitro but 
also in the intracellular environment. 
Research for new antimicrobial agents remains the 
most promising approach to the problem of emerging 
mycobacterial infections evermore resistant to available 
antibiotics. In this study we have isolated a strain of B. 
pumilus capable of inhibiting mycobacterial growth (M. 
smegmatis, M. aurum A+ and M. bovis BCG) through the 
action of a protein metabolite. This metabolite is nontoxic, 
capable of accumulating within the macrophage, resisting 
the   intracellular   environment   of   the  phagocytes  and  
  






Figure 1. The cytotoxicity assay 
I: peritoneal macrophages treated with the antimycobacterial substance. 
II: peritoneal macrophages treated with LB medium protein extract. 
III: peritoneal macrophages treated with SDS. 
IV: Untreated peritoneal macrophages. 
The Student t test revealed significant difference between groups (I, II, IV) 






Figure 2. Action of the antimycobacterial substance from B. pumilus against M. 
smegmatis hosted by peritoneal macrophages 
I: CFU of M. smegmatis surviving inside macrophages after treatment with B. 
pumilus metabolite. 
II: CFU of M. smegmatis surviving inside macrophages after treatment with 
Amikacin. 
III: CFU of M. smegmatis surviving inside untreated macrophages. 
The Student test revealed significant difference between groups (I, II) and the 
group III. 
  




inactivating the bacilli with efficiency comparable to the 
pure commercial antimycobacterial substance Amikacin. 
The structure and mode of action of the metabolite from 
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